As global markets navigate a period of volatility, with tech stocks facing pressure and value-oriented segments gaining traction, Asia's stock markets are also experiencing fluctuations influenced by economic data and geopolitical factors. In this environment, identifying undervalued stocks requires careful analysis of companies that may benefit from shifting investor preferences towards sectors less exposed to recent market disruptions.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| Zhaojin Mining Industry (SEHK:1818) |
HK$32.44 |
HK$64.09 |
49.4% |
| Ningxia Building Materials GroupLtd (SHSE:600449) |
CN¥13.62 |
CN¥26.70 |
49% |
| Helens International Holdings (SEHK:9869) |
HK$0.91 |
HK$1.77 |
48.7% |
| HD Renewable Energy (TWSE:6873) |
NT$108.00 |
NT$213.27 |
49.4% |
| Fuji Media Holdings (TSE:4676) |
¥3560.00 |
¥7042.73 |
49.5% |
| EROAD (NZSE:ERD) |
NZ$0.97 |
NZ$1.88 |
48.4% |
| DIGITAL HEARTS HOLDINGS (TSE:3676) |
¥878.00 |
¥1727.05 |
49.2% |
| CURVES HOLDINGS (TSE:7085) |
¥764.00 |
¥1527.45 |
50% |
| Auntea Jenny (Shanghai) Industrial (SEHK:2589) |
HK$85.80 |
HK$169.87 |
49.5% |
| Asia-potash International Investment (Guangzhou)Co.Ltd (SZSE:000893) |
CN¥56.59 |
CN¥109.88 |
48.5% |
Let's dive into some prime choices out of the screener.
Hugel
Overview:Hugel, Inc. is a company that develops and manufactures biopharmaceuticals both in South Korea and internationally, with a market capitalization of ₩2.85 trillion.
Operations:The company's revenue segments include the development and manufacturing of biopharmaceuticals for both domestic and international markets.
Estimated Discount To Fair Value:33.4%
Hugel, Inc. is trading at a 33.4% discount to its estimated fair value and significantly below future cash flow value, suggesting it may be undervalued based on cash flows. The company reported KRW 425.1 billion in sales and KRW 138 billion in net income for 2025, with earnings expected to grow over 20% annually for the next three years. Hugel's strategic expansion into the U.S., including a hybrid sales model, aims to enhance profitability and market share.
-
Our growth report here indicates Hugel may be poised for an improving outlook.
-
Click here to discover the nuances of Hugel with our detailed financial health report.
APR
Overview:APR Co., Ltd. manufactures and sells cosmetic products for men and women, with a market cap of ₩10.56 billion.
Operations:The company's revenue segments include ₩1.54 billion from cosmetics and ₩38.63 million from the clothing fashion sector, with important adjustments of -₩358.74 million.
Estimated Discount To Fair Value:21.5%
APR Co., Ltd. is trading 21.5% below its estimated fair value and more than 20% under future cash flow value, highlighting potential undervaluation based on cash flows. The company forecasts a revenue increase to ₩2.1 trillion in 2026 with a 25% operating margin range, reflecting robust growth prospects. Earnings grew by 165.3% last year and are expected to continue growing significantly at over 30% per year, outpacing the KR market's growth rate.
-
According our earnings growth report, there's an indication that APR might be ready to expand.
-
Click here and access our complete balance sheet health report to understand the dynamics of APR.
Shanghai OPM Biosciences
Overview:Shanghai OPM Biosciences Co., Ltd. operates by providing cell culture media and CDMO services both in China and internationally, with a market cap of CN¥6.92 billion.
Operations:Shanghai OPM Biosciences generates revenue through its provision of cell culture media and CDMO services across domestic and international markets.
Estimated Discount To Fair Value:35.7%
Shanghai OPM Biosciences is trading at CN¥53.18, significantly below its estimated future cash flow value of CN¥82.74, suggesting it may be undervalued based on cash flows. Revenue growth is projected at 19.9% annually, outpacing the broader Chinese market's 14.8%. Earnings are expected to grow significantly at 46.5% per year over the next three years, though return on equity remains low and dividends are not well covered by free cash flows.
Seize The Opportunity
-
Gain an insight into the universe of 231 Undervalued Asian Stocks Based On Cash Flows by clicking here.
-
Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
-
Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Want To Explore Some Alternatives?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A145020 KOSE:A278470 and SHSE:688293.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
